Immuron Receives $1.59M R&D Tax Concession Refund
Nov 29, 2016 14:01 pm UTC| Business
MELBOURNE, Australia, Nov. 29, 2016 -- Immuron Limited (ASX:IMC) is pleased to announce that under the Australian Government’s Research and Development Income Tax Concession incentive program, the Company has received a...
Immuron Receives $1.59M R&D Tax Concession Refund
Nov 29, 2016 14:01 pm UTC| Business
MELBOURNE, Australia, Nov. 29, 2016 -- Immuron Limited (ASX:IMC) is pleased to announce that under the Australian Government’s Research and Development Income Tax Concession incentive program, the Company has received a...
SharpSpring to Present at the LD Micro Main Event on December 7, 2016
Nov 29, 2016 14:01 pm UTC| Business
GAINESVILLE, Fla., Nov. 29, 2016 -- SharpSpring, Inc. (NASDAQ:SHSP), a global provider of cloud-based marketing technologies, has been invited to present at the LD Micro Main Event. The conference is being held on...
SharpSpring to Present at the LD Micro Main Event on December 7, 2016
Nov 29, 2016 14:01 pm UTC| Business
GAINESVILLE, Fla., Nov. 29, 2016 -- SharpSpring, Inc. (NASDAQ:SHSP), a global provider of cloud-based marketing technologies, has been invited to present at the LD Micro Main Event. The conference is being held on...
AXIM® Biotech Files IP Application on Propietary Method to Extract High-Purity THC
Nov 29, 2016 14:01 pm UTC| Business
Proprietary method in collaboration with Syncom B.V. will achieve a THC purity level of Greater than 95% NEW YORK, Nov. 29, 2016 -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in...
AXIM® Biotech Files IP Application on Propietary Method to Extract High-Purity THC
Nov 29, 2016 14:01 pm UTC| Business
Proprietary method in collaboration with Syncom B.V. will achieve a THC purity level of Greater than 95% NEW YORK, Nov. 29, 2016 -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in...
PharmaCyte Biotech Granted FDA Pre-IND Meeting for Pancreatic Cancer Therapy
Nov 29, 2016 14:01 pm UTC| Business
LAGUNA HILLS, Calif., Nov. 29, 2016 -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell...